Background: Chronic hepatitis B has become a major public health problem in China. An accurate depiction of the disease burden has not yet been thoroughly conducted. We aimed to project the disease burden of chronic hepatitis B virus infection and related complications by modeling various scenarios. Method : An individual-based Markov model was used to predict disease burden from 2006 through 2050. We simulated 5 scenarios with different annual incidences, diagnosis and nucleotide analogs (NAs) treatment rates as well as treatment eligibility, which included a natural history without diagnosis or NAs therapy, a base-case, a World Health Organization proposed target case and two ideal cases. Result: Natural history scenario is projected to have the fewest HBsAg loss (27.59 million) and highest HBV-related deaths (27.19 million). With improved diagnosis and treatment rates of NAs therapy, ideal cases have fewer HBV-related deaths (14.46-14.77 million) than WHO (15.13 million) and base-case (16.89 million), but proportion of HBsAg loss is similar among them. With reduced new infections, prevalence of chronic HBV in 2050 is expected minimally to be 27.03-27.49 million under WHO and ideal cases.
Introduction Chronic hepatitis B virus (HBV) infection has always been a major public health issue in
China. In the latest nationwide seroepidemiologic survey, conducted in 2006, the prevalence rate of HBsAg positivity in the general population was 7.18% (1) . Although an updated survey was re-conducted in 2014, it only covered 1-29 years old age population (2) . Based on this data, approximately 93 million people were chronically infected with HBV. People living with chronic HBV infection can be classified into several categories according to serum markers and liver function (3, 4) , including immune-tolerant carrier, inactive carrier, HBeAg positive hepatitis, HBeAg negative hepatitis. In 2006, the estimated 63-73 million inactive carriers made up the largest group (4) (5) (6) .
A main concern about chronic HBV infection is its long-term complications. Chronic HBV infection carries a risk of developing primary liver cancer, which ranks as the sixth most common cancer worldwide (7) . It also leads to 786,000 HBV-related deaths per year, making it the tenth leading cause of death worldwide (8) . Over their lifetimes, 15-40% of people with chronic HBV infection can develop complications ranging from hepatocellular carcinoma (HCC) to HBV-related death (9) .
Considering these potential progressions and adverse outcomes, the World Health Organization (WHO) endorsed its first global health sector strategy on viral hepatitis in 2016 with the goal of eliminating hepatitis B and C by 2030 (10) . There are various ways to achieve this goal, including preventing new infections and treating current cases. For those already infected, a 'functional cure' (HBsAg loss) is the only method available. The international guidelines also suggested treatment for those who are eligible as well as continued monitoring of all currently infected individuals (11) . Nucleos(t)ide analogs (NAs) therapy was first introduced around 2000. Since 2005, high-potency NAs with minimal risk and side effects, such as Entecavir (ETV), have been widely applied in China as the firstline recommendation (12, 13) . Recently China has updated chronic HBV treatment guideline expanding NAs treatment eligibility (14).
There were several HBV modeling studies evaluated the epidemiology of chronic HBV infection in China (15) (16) (17) . Those studies found that increasing screen and treatment were effective in reducing chronic HBV infection, enhancing vaccination was beneficial for 4 eliminating transmission. However, previous studies barely projected HBV complicated diseases including cirrhosis, DC, HCC, liver transplantation clearly. Meanwhile, there is no cohort study in China so far could accurately follow up long-term outcomes of all HBV infected population, which is quite important to systematic assessment of health consequence and decision-making. Therefore, our study developed an individual-level 
Patient demographics
Our study constructed a simulated chronic HBV-infected population representing nationwide baseline in 2006 using results of national survey of chronic HBV infection epidemiologic study (18, 19) (Supplementary Table 3 and Supplementary Table 10 ). New HBV infections after 2006 were added into simulated population annually based on reports 5 by the Chinese Center for Disease Control and Prevention, and the age distribution was derived from published data. Since there is no data regarding to age structure after 2017, we adopted the same distribution as 2017 (20) (21) (22) (Supplementary Table 4 ).
Model schematics
In natural history, we simplified and organized chronic HBV infection status into three 'CHB states' including HBsAg-positive inactive carrier, HBeAg-negative hepatitis, HBeAgpositive hepatitis, four 'Complication states' including cirrhosis, DC, HCC, LT, and three absorbing states including HBsAg loss, background death, HBV-related death ( Supplementary Fig. 2 ). Each 'CHB state', at predefined probability rates, could either progress into cirrhosis and HCC states, or undergo HBsAg loss or background death as absorbing states. All of 'Complication states' could transfer to each other or undergo HBVrelated death ( Supplementary Fig. 2 and Supplementary Table 1 ). We also modeled annual probability of non-liver death. Background mortality of age-standardized rate (ASR) was estimated from the National Bureau of Statistics of China (23) .
We didn't consider immune tolerance as one of states here, which is common among infants and children, due to less epidemiologic data are available and the largest population consist of chronic HBV infection in adults is inactive carriers in China (5, (24) (25) (26) .
We also assumed those who met treatment criteria in Chinese Medical Association and Asian Pacific Association for the Study of the Liver (APASL) guidelines in HBeAg-negative hepatitis, HBeAg-positive hepatitis and cirrhosis states could receive NAs therapy and achieve virological response (defined as undetectable serum HBV DNA during therapy), thereafter progress at different probability rates in Supplementary Table 2 (4, 27) . For those who did not achieve virological response, we assumed them to have same progression as natural history. For DC, HCC, or LT patients, we assumed the progression 6 rate was relatively constant regardless of NAs therapy.
We did not different strategies of HBV vaccination in our model because currently it has already covered universally with more than 95% coverage and vertical transmission block is also highly effective with less than 10/100 000 new HBV infection incidence (28, 29) .
Meanwhile, vaccine's effect have already been shown as new infection number every year in our model. And we simulated only NAs therapy, electing not to include interferon therapy due to its finite coverage, numerous side effects and contraindications (13) .
HBV diagnosis, awareness, and treatment
We adopted a recent study summarized diagnosis and treatment rates (treatment/treatment eligible) in China (18.7% and 10.8%, respectively, in 2016) as the base-case parameters in our model (20) . Under WHO targets and ideal cases scenario, we used data from WHO proposed 'elimination of viral hepatitis' in 2016 as diagnosis and treatment rates. We assumed that newly enrolled individuals were neither undiagnosed nor unaware at first, and they could become diagnosed at a certain probability. Once diagnosed, patients were assumed to accept their condition and awareness of HBV infection. Newly treated individuals were divided into virological response or nonvirological response state, which were permanent until simulation ended.
Simulation scenarios
We simulated five scenarios with different diagnosis rate, treatment rate, treatment eligibility and new infection annually ( 
Sensitivity analysis
We did a 1-way sensitivity analysis on the model in base-case parameters by considering uncertainty in all probability rates. We defined each annual transition probability using the upper range and lower range values, then compared upper or lower values of cirrhosis, DC, HCC, LT cumulative incidence and cumulative death with base-case values.
(Supplementary S 6).
Result Validation and sensitivity analysis
Our model projected that the total number of chronic HCV infection in 2016 was 86 million, which is equal to the reported epidemiologic data. The projected annual incidence of HCC in 2010 to 2018 and HBV-related death in 2018 were within 13% of the reported values except one data (30-33) ( Supplementary Table 6 ). Finally, our model's 10-
year cumulative incidence rates of HBsAg loss, hepatitis in inactive carrier closely matched those of a published real-world study (34) (Supplementary Table 7 ).
Sensitivity analysis revealed that 81.75% (327/400) of all predicted upper or lower values of cirrhosis, DC, HCC, LT cumulative incidence and cumulative death fluctuated within 10%, 96% (384/400) were fluctuated within 20%. (Supplementary Table 8 ) Similarly, proportion of HBV-related among base-case (19.35%), WHO (18.53%), ideal 1(17.99%) and ideal 2 (17.62%) scenarios were far less than natural history (31.00%) ( Table 2 ).
Incidence of chronic HBV complications and death
The cumulative and annual incidence of HBV-related complications and death were presented in Fig. 2 and Supplementary Fig. 3 . We projected that there would be a total of 379.66 million cumulative incidence of HBV-related complications and 241.61 million death under natural history scenario ( Supplementary Table 11 ). Compared to natural history, cumulative incidence of HBV-related complications was predicted to reduce significantly to 251.59 million, 230.38 million, 215.19 million, and 218.32 million under scenarios 2-5. Among four complications, cumulative incidence of cirrhosis was found to have the largest decline with 39.87%, 49.09%, 51.61%, and 52.77% reduction under four non-natural history scenarios. Annual incidence of HBV-related complications and death were presented in Fig. 3 and Supplementary Fig. 4 . In 2050, HCC death was predicted to be the most common cause of both HBV-related complications and death; corresponding annual incidence of HCC yielded to 411440, 258010, 168840, 147270, and 165330 respectively under five scenarios.
Annual incidence of HBeAg negative and positive hepatitis B
Our model also predicted a decreasing trend of annual incidence of HBeAg negative and positive hepatitis in Fig. 4 . We estimated annual incidence of HBeAg negative hepatitis was lowest among all the scenarios under natural history from 2006 (1.69 million) to 2023 (1.13 million). Thereafter the annual incidence in natural and base-case became close and higher than the other three scenarios. (Fig. 4A ). Estimated annual incidence of HBeAgpositive hepatitis under natural history was constantly highest among all the scenarios; the incidence in 2050 yielded to 294430, more than five times than ideal 2 (54255) ( Fig. 4B ).
Prevalence of total chronic HBV infection
The trend of total chronic HBV infection prevalence over time was presented in 100% diagnostic modalities and treatment rates simulated in ideal 1 scenario projected more HBsAg loss, less HBV-related death and less total chronic HBV infected prevalence than gradually increased diagnosis and treatment rates under WHO targeted scenario.
Current HBV screen in China only includes childbirth screen and vaccination, blood products screen, and safe injection practices screen (35) . More than 80% HBV infections are unaware about their HBV status (20) .In the United States, screen is recommended for those who are at high risk including immigrants from places with > 2% prevalence, HIVinfected people, and pregnant women at their first prenatal visits (36, 37) . According to that standard, implementing 100% HBV screen and achieving full diagnosis to all Chinese is clinically significant due to medium-high prevalence nationwide.
Similarly, ideal 2 scenario led to fewer HBV-related deaths and more HBsAg loss than WHO targeted scenario, which proved increased treatment eligibility was beneficial in reducing chronic HBV disease burden. In the past, only hepatitis patients with 2 times higher upper limit of normal ALT met the treatment eligibility in China; but recently newest Chinese guideline suggested full treatment to all hepatitis patients with elevated ALT (14). Our model result provided theoretical evidence and clearly endorsed the recommendation of increasing treatment eligibility by newest Chinese guideline.
We also observed a huge disparity of total prevalence between base-case and WHO targeted scenario, which mostly derived from different setting of annual new infection.
Diagnosis and treatment rate only contributed minor difference compared with reduced new infection. Therefore, controlling new infection is the most effective method to lower chronic HBV disease burden now available. Although Chinese government administered birth immunization after birth since 1992 and achieved significant reduction on total HBV prevalence, there are still 50,000 vertical transmission and 800 thousands new infection every year. (1, 20, 38, 39) New infections were found to be more common in undeveloped region and those who born before 1992 without vaccine protection (40) .Thus, more efforts are still needed especially on birth immunization of remote region and catch-up vaccine for susceptible adults.
In addition, cumulative incidences of cirrhosis, DC, HCC, and related deaths were predicted increasing over time under all scenarios, implying that NAs therapy could only decelerate but not reverse the growing trend. The potential attribution was supposed that only a small group of patients receiving NAs therapy would reach 'functional cure' status (41) . Even with the help of Peg-IFN therapy, 3-7% of patients would loss HBsAg, far less than 97% of HCV elimination using DAAs (3, 42, 43) . Also, the huge baseline of infected population would generate large disease burden of hepatitis and complications every year, largely exceeded HBsAg loss individuals in number. These two reasons explain why DAAs could convert the increasing trend of HCV complications as shown in our previous modeling study but not NAs therapy in HBV (44) . Hence, we suggest that without high potency new drugs, it will be hard to avert increasing trend of cumulative cirrhosis, DC,
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HCC, LT and HBV-related death.
Our study has several limitations as a modeling study could never exactly simulate an actual situation, particularly with such complicated disease progression. 1) The parameters chosen in the model were selected from different published articles. We 
Conclusion And Implication
Our finding suggested that if the future disease burden of chronic HBV is to be lowered dramatically, the government needs to control new infection as priority such as consolidate and further expand birth immunization, and catch-up vaccine for adults.
Meanwhile, without high potency new drugs, it will be hard to avert increasing trend of cumulative cirrhosis, DC, HCC, LT and HBV-related death. 
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